PHARMACEUTICAL | DRY EYE

Pipeline

Acoltremon (AR-15512) is an investigational drug and is not currently commercially available.

About Acoltremon

Acoltremon, a topical agonist of transient receptor potential melastatin 8 (TRPM8), is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease.

For more information about dry eye disease, please visit
Understanding Dry Eye.

Clinical Trials for Acoltremon

Pivotal studies for Acoltremon have been successfully completed.

For a comprehensive overview of the COMET clinical development program, please explore this interactive resource.

EXPLORE COMET CLINICAL TRIALS

Scientific Publications and Abstracts

DRY EYE CLINICAL TRIAL

Acoltremon (AR-15512) is an agonist of the transient receptor potential melastatin 8 receptor.

READ ARTICLE